Mycophenolate Mofetil (MYC) is a transplant drug used to prevent rejection in heart and kidneys transplant patients. Inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in de novo synthesis of guanosine nucleotides, was considered as a primary target for MYC. Recently, we described that MYC was activates aryl hydrocarbon receptor and it antagonizes glucocorticoid receptor. Here we describe an androgen receptor (AR) as another off-target for MYC. We found that MYC increased basal and dihydrotestosterone (DHT)-inducible AR-dependent luciferase activity in AIZ-AR cells. In the same manner it induced or augmented mRNA level of KLK3 (prostate specific antigen; PSA) in 22Rv1 cells. Herein it displayed a hormetic effect on proliferation activity, since it significantly stimulated proliferation in lower concentrations but inhibited in higher (>1 µg/ml) concentrations in the presence of DHT. In contrast, MYC suppressed DHT-inducible KLK3 mRNA expression and cell proliferation in androgen-dependent LNCaP cells. MYC augmented DHT-inducible nuclear translocation of AR and increased the expression of MAPK8/9 (JNK46/54) resulting in the drop of their phosphorylation status. Moreover, MYC sensitized DHT-treated 22Rv1 cells to JNK-IN-8 mediated growth inhibition with the drop of IC50 from 1425 nM to 84 nM within 24 hrs. In conclusion, we suggest that, castrate-resistant prostate cancers progression might be retarded with the combination of MYC and chemical JNK inhibitors, involving AR-dependent mechanism.

Department of Cell Biology and Genetics Faculty of Science Palacky University in Olomouc Slechtitelu 27 Olomouc CZ 783 71 Czech Republic

Zobrazit více v PubMed

Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. The Journal of biological chemistry. 1993;268:27286–90. PubMed

Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2005;33:139–46. PubMed

Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H. et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clinical transplantation. 2000;14:179–88. PubMed

Vrzal R, Zenata O, Bachleda P, Dvorak Z. The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicology in vitro: an international journal published in association with BIBRA. 2015;29:1088–99. PubMed

Dun B, Xu H, Sharma A, Liu H, Yu H, Yi B. et al. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid. International journal of clinical and experimental pathology. 2013;6:2880–6. PubMed PMC

Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2007;20:1085–94. PubMed

Fellenberg J, Kunz P, Sahr H, Depeweg D. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PloS one. 2010;5:e12179. PubMed PMC

Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. International journal of cancer Journal international du cancer. 2008;123:2294–302. PubMed PMC

Bartonkova I, Novotna A, Dvorak Z. Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity. PloS one. 2015;10:e0121316. PubMed PMC

Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B. et al. Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chemico-biological interactions. 2010;185:253–62. PubMed

Olejarz W, Bryk D, Zapolska-Downar D, Malecki M, Stachurska A, Sitkiewicz D. Mycophenolic acid attenuates the tumour necrosis factor-alpha-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways. European journal of clinical investigation. 2014;44:54–64. PubMed

Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T. et al. Discovery of potent and selective covalent inhibitors of JNK. Chemistry & biology. 2012;19:140–54. PubMed PMC

Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S. et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant immunology. 1998;6:251–9. PubMed

Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal cord. 2003;41:610–9. PubMed

Blaheta RA, Bogossian H, Beecken WD, Jonas D, Hasenberg C, Makarevic J. et al. Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro. Transplantation. 2003;76:1735–41. PubMed

Owens GC, Orr EA, DeMasters BK, Muschel RJ, Berens ME, Kruse CA. Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res. 1998;58:2020–8. PubMed

Edvardsen K, Pedersen PH, Bjerkvig R, Hermann GG, Zeuthen J, Laerum OD. et al. Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. International journal of cancer Journal international du cancer. 1994;58:116–22. PubMed

Blaheta RA, Hundemer M, Mayer G, Vogel JU, Kornhuber B, Cinatl J. et al. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell communication & adhesion. 2002;9:131–47. PubMed

Leckel K, Beecken WD, Jonas D, Oppermann E, Coman MC, Beck KF. et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clinical and experimental immunology. 2003;134:238–45. PubMed PMC

Engl T, Makarevic J, Relja B, Natsheh I, Muller I, Beecken WD. et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC cancer. 2005;5:4. PubMed PMC

David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clinical transplantation. 2005;19:279–85. PubMed

Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005;5:2954–60. PubMed

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22. PubMed PMC

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–13. PubMed PMC

Li Y, Xie N, Gleave ME, Rennie PS, Dong X. AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget. 2015;6:33743–54. PubMed PMC

Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 2015;6:27440–60. PubMed PMC

Jiang SJ, Wang S. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36:8177–84. PubMed